Recent Updates
Recently added Catalysts

CNTO 6785 /kg

Phase 1

Healthy | Small molecule | Other |Johnson & Johnson|Last Updated: Jan 28, 2013

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment32
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01288196A Safety, Tolerability, Pharmacokinetics, and Immunogenicity Study of CNTO 6785 in Healthy VolunteersPHASE1 COMPLETED 32Feb 1, 2011Aug 1, 2011Jan 28, 20131 Belgium
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number and type of adverse events reported
Up to Week 17
Number and type of Infusion (injection) site reactions
Up to Week 17
Vital signs measurements
Up to Week 17
Clinical laboratory test results
Up to Week 17
Findings from cardiology assessments (electrocardiograms [ECGs] and cardiac telemetry)
Up to Week 17
Secondary Endpoints
Serum concentration of CNTO 6785
Up to Week 17
Serum antibodies to CNTO 6785
Up to Week 17
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
001EXPERIMENTALCNTO 6785 1 mg/kg IV A single 30-minute IV infusion of CNTO 6785 1 mg/kg
002EXPERIMENTALCNTO 6785 3 mg/kg IV A single 30-minute IV infusion of CNTO 6785 3 mg/kg
003EXPERIMENTALCNTO 6785 10 mg/kg IV A single 30-minute IV infusion of CNTO 6785 10 mg/kg
004PLACEBO_COMPARATORPlacebo IV A single 30-minute IV infusion of placebo
005EXPERIMENTALCNTO 6785 SC A single SC dose of CNTO 6785 (3 mg/kg) administered in up to 3 SC injections
006PLACEBO_COMPARATORPlacebo SC A single SC dose of placebo administered in up to 3 SC injections
Interventions
NameTypeDescription
Placebo IVDRUGA single 30-minute IV infusion of placebo
CNTO 6785 1 mg/kg IVDRUGA single 30-minute IV infusion of CNTO 6785 1 mg/kg
CNTO 6785 3 mg/kg IVDRUGA single 30-minute IV infusion of CNTO 6785 3 mg/kg
CNTO 6785 10 mg/kg IVDRUGA single 30-minute IV infusion of CNTO 6785 10 mg/kg
CNTO 6785 SCDRUGA single SC dose of CNTO 6785 (3 mg/kg) administered in up to 3 SC injections
Placebo SCDRUGA single SC dose of placebo administered in up to 3 SC injections
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Healthy adult volunteer with no clinically significant abnormalities as determined by the investigator (study physician) * Have a body mass index (BMI) between 19-30 kg/m2 * Be a non-smoker for at least 6 months prior to study participation * Women must be postmenopausal or su...

Countries:Belgium
Unlock Eligibility Criteria